文献速递乳腺癌

新辅助帕博西利联合吉瑞司群或阿那曲唑治疗雌激素受体阳性、HER2阴性早期乳腺癌(coopERA乳腺癌研究):一项开放标签、随机、对照、2期研究

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
PubMed 文献 · Lancet Oncol · 2023-01-01

coopERA乳腺癌研究纳入221例绝经后雌激素受体阳性、HER2阴性未经治疗的早期乳腺癌患者,随机分配至吉瑞司群联合帕博西利组或阿那曲唑联合帕博西利组。主要终点分析显示,吉瑞司群组从基线至第2周Ki67几何均值相对降低75%,阿那曲唑组降低67%,差异有统计学意义(p=0.043)。吉瑞司群单药及联合帕博西利均显示出抗增殖和抗肿瘤活性,且耐受性良好。

要点

  • 吉瑞司群组第2周Ki67几何均值相对降低75%,阿那曲唑组降低67%,p=0.043。
  • 最常见3-4级不良事件为中性粒细胞减少(吉瑞司群组26% vs 阿那曲唑组27%)。
  • 吉瑞司群组严重不良事件5例(4%),阿那曲唑组2例(2%),无治疗相关死亡。

核心结论

  • 吉瑞司群单药及联合帕博西利均显示出令人鼓舞的抗增殖和抗肿瘤活性,且耐受性良好。
  • 研究结果支持在正在进行的试验中进一步研究吉瑞司群。

研究设计与样本

  • 开放标签、随机、对照、2期研究,在全球11个国家的59个医院或诊所站点开展。
  • 纳入221例绝经后女性,年龄≥18岁,临床T分期cT1c至cT4a-c(cT1c中≥1.5 cm),雌激素受体阳性、HER2阴性、未经治疗的早期乳腺癌,ECOG体能状态0-1,基线Ki67评分至少5%。
  • 按1:1随机分配至吉瑞司群30 mg口服每日一次组(n=112)或阿那曲唑1 mg口服每日一次组(n=109),第1-14天为窗口机会期。
  • 随机化按cT分期、基线Ki67评分和孕激素受体状态分层。
  • 随后16周新辅助期包括相同内分泌方案联合帕博西利125 mg口服每日一次,每28天周期第1-21天给药,共4个周期。

主要发现

  • 2020年9月4日至2021年6月22日期间入组221例患者,吉瑞司群联合帕博西利组112例(中位年龄62.0岁,IQR 57.0-68.5),阿那曲唑联合帕博西利组109例(中位年龄62.0岁,IQR 57.0-67.0)。
  • 221例患者中,15例(7%)为亚洲人,3例(1%)为黑人或非裔美国人,194例(88%)为白人,9例(4%)种族未知。
  • 主要分析数据截止(2021年7月19日),从基线至第2周Ki67几何均值相对降低:吉瑞司群组-75%(95% CI -80至-70),阿那曲唑组-67%(-73至-59),p=0.043,达到主要终点。
  • 最终分析数据截止(2021年11月24日),最常见3-4级不良事件为中性粒细胞减少(吉瑞司群联合帕博西利组29/112例[26%] vs 阿那曲唑联合帕博西利组29/109例[27%])和中性粒细胞计数降低(17例[15%] vs 16例[15%])。
  • 严重不良事件:吉瑞司群联合帕博西利组5例(4%),阿那曲唑联合帕博西利组2例(2%);无治疗相关死亡;吉瑞司群联合帕博西利组1例患者因不良事件(心肌梗死)死亡。

关键数值与推荐

  • 主要终点:第2周Ki67几何均值相对降低,吉瑞司群组-75%(95% CI -80至-70)vs 阿那曲唑组-67%(-73至-59),p=0.043。
  • 3-4级中性粒细胞减少:吉瑞司群联合帕博西利组26%(29/112)vs 阿那曲唑联合帕博西利组27%(29/109)。
  • 3-4级中性粒细胞计数降低:吉瑞司群联合帕博西利组15%(17/112)vs 阿那曲唑联合帕博西利组15%(16/109)。
  • 严重不良事件:吉瑞司群联合帕博西利组4%(5/112)vs 阿那曲唑联合帕博西利组2%(2/109)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of more potent selective oestrogen receptor antagonists and degraders (SERDs) that can be orally administered could help to address the limitations of current endocrine therapies. We report the primary and final analyses of the coopERA Breast Cancer study, designed to test whether giredestrant, a highly potent, non-steroidal, oral SERD, would show a stronger anti-proliferative effect than anastrozole after 2 weeks for oestrogen receptor-positive, HER2-negative, untreated early breast cancer. METHODS: In this open-label, randomised, controlled, phase 2 study, postmenopausal women were eligible if they were aged 18 years or older; had clinical T stage (cT)1c to cT4a-c (≥1·5 cm within cT1c) oestrogen receptor-positive, HER2-negative, untreated early breast cancer; an Eastern Cooperative Oncology Group performance status of 0-1; and baseline Ki67 score of at least 5%. The study was conducted at 59 hospital or clinic sites in 11 countries globally. Participants were randomly assigned (1:1) to giredestrant 30 mg oral daily or anastrozole 1 mg oral daily on days 1-14 (window-of-opportunity phase) via an interactive web-based system with permuted-block randomisation with block size of four. Randomisation was stratified by cT stage, baseline Ki67 score, and progesterone receptor status. A 16-week neoadjuvant phase comprised the same regimen plus palbociclib 125 mg oral daily on days 1-21 of a 28-day cycle, for four cycles. The primary endpoint was geometric mean relative Ki67 score change from baseline to week 2 in patients with complete central Ki67 scores at baseline and week 2 (window-of-opportunity phase). Safety was assessed in all patients who received at least one dose of study drug. The study is registered with ClinicalTrials.gov (NCT04436744) and is complete. FINDINGS: Between Sept 4, 2020, and June 22, 2021, 221 patients were enrolled and randomly assigned to the giredestrant plus palbociclib group (n=112; median age 62·0 years [IQR 57·0-68·5]) or anastrozole plus palbociclib group (n=109; median age 62·0 [57·0-67·0] years). 15 (7%) of 221 patients were Asian, three (1%) were Black or African American, 194 (88%) were White, and nine (4%) were unknown races. At data cutoff for the primary analysis (July 19, 2021), the geometric mean relative reduction of Ki67 from baseline to week 2 was -75% (95% CI -80 to -70) with giredestrant and -67% (-73 to -59) with anastrozole (p=0·043), meeting the primary endpoint. At the final analysis (data cutoff Nov 24, 2021), the most common grade 3-4 adverse events were neutropenia (29 [26%] of 112 in the giredestrant plus palbociclib group vs 29 [27%] of 109 in the anastrozole plus palbociclib group) and decreased neutrophil count (17 [15%] vs 16 [15%]). Serious adverse events occurred in five (4%) patients in the giredestrant plus palbociclib group and in two (2%) patients in the anastrozole plus palbociclib group. There were no treatment-related deaths. One patient died due to an adverse event in the giredestrant plus palbociclib group (myocardial infarction). INTERPRETATION: Giredestrant offers encouraging anti-proliferative and anti-tumour activity and was well tolerated, both as a single agent and in combination with palbociclib. Results justify further investigation in ongoing trials. FUNDING: F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Hurvitz SA, Bardia A, Quiroga V, et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023. PMID: 37657462. doi:10.1016/S1470-2045(23)00268-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。